Micafungin Mylan (Micafungin)

Micafungin blocks the enzyme β-(1,3)-D-glucan synthase, which is essential for building β-(1,3)-D-glucan, a key structural component of the fungal cell wall. Inhibiting this pathway weakens the wall, causing osmotic instability and ultimately leading to fungal cell death.

The prescribed dose is set by the treating clinician based on the specific infection, its severity, the patient’s renal and hepatic function, and any relevant clinical guidelines. Micafungin dosing is individualized and should not be altered without medical direction.

Pregnancy safety data are limited and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding considerations are similar; the decision should be made in consultation with a healthcare professional.

Enquiries can be submitted on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to ergosterol. Echinocandins like micafungin often have fewer drug‑drug interactions and are effective against many azole‑resistant Candida species, but they are administered intravenously.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Prior to use, inspect the vial for particulate matter and ensure aseptic technique during preparation and administration.

Micafungin Mylan is supplied as a sterile injection for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30‑60 minutes, according to the dose prescribed by the treating physician.

Serious adverse events include hepatotoxicity (significant liver enzyme elevations or liver failure), severe hypersensitivity reactions such as anaphylaxis, and infusion‑related reactions that may cause hypotension, respiratory distress, or chest discomfort. Prompt medical evaluation is required if these occur.

Patients with a known hypersensitivity to micafungin or any component of the formulation should avoid the drug. Caution is advised in individuals with severe hepatic impairment, and the medication should be used only under specialist supervision in such cases.